Enrollment

Assessed for eligibility (n=835)

Excluded (n=615)
- Did not meet inclusion criteria (n=254)
- Declined to participate (n= 350)
- Moved to another hospital (n= 11)

Randomized (n=220)

Allocation

Received Active intervention (n= 111)
- Did not complete initial assessment (n= 0)
- Available for analysis (n=111)

Received Placebo intervention (n= 109)
- Did not complete initial assessment (n= 1)
- Recruitment data lost (n= 1)
- Available for analysis (n=107)

Week 2 Follow-up

Available for analysis (n= 106)
Lost to follow-up (i.e. deceased, withdrawn, could not contact) (n= 5)

Available for analysis (n= 106)
Lost to follow-up (i.e. deceased, withdrawn, could not contact) (n= 1)

Week 4 Follow-up

Available for analysis (n= 106)
Lost to follow-up (i.e. deceased, withdrawn, could not contact) (n= 1)

Available for analysis (n= 104)
Lost to follow-up (i.e. deceased, withdrawn, could not contact) (n= 2)

Week 12 Follow-up

Available for analysis (n= 85)
Lost to follow-up (i.e. deceased, withdrawn, could not contact) (n= 21)

Available for analysis (n= 84)
Lost to follow-up (i.e. deceased, withdrawn, could not contact) (n= 20)

Week 26 Follow-up

Available for analysis (n= 83)
Lost to follow-up (i.e. deceased, withdrawn, could not contact) (n= 2)

Available for analysis (n= 80)
Lost to follow-up (i.e. deceased, withdrawn, could not contact) (n= 4)

Figure 2: Comorbidity types, percentages (n=217)